Article
Chronic Lymphocytic Leukemia: Molecular Pathologies and Therapeutic Strategies
2026-04-21
Abstract excerpt
Therapy for chronic lymphocytic leukemia (CLL) has evolved dramatically with the introduction of targeted agents, particularly Bruton tyrosine kinase inhibitors (BTKis) and BCL2 inhibitors (BCL2is). This review summarizes contemporary frontline and relapsed/refractory treatment strategies, with an emphasis on molecular risk stratification, combination and triplet regimens, measurable residual disease (MRD)–guided...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- ee3ec195-55bb-51eb-9dc8-a45122a25bbc
- DOI
- 10.20944/preprints202604.1378.v1
